Navidea sells shares to support continuing operations

04/24/2013 | Wall Street Journal, The

Navidea Biopharmaceuticals said it has sold shares to JPMorgan Chase & Co.'s asset management unit along with another investor. The company anticipates raising $5.1 million from the move. "We are pleased to be able to capitalize on this opportunity to strengthen our institutional ownership base as we work toward the launch of our first commercial radiopharmaceutical agent, Lymphoseek," said Navidea President and CEO Mark Pykett.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ